Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma: A Japan Clinical Oncology Group Study, JCOG 9301

International Journal of Hematology

Volumn 79, Issue 2, 2004, Pages 165-173

  Takenaka, Takeaki ^a   Itoh, Kuniaki ^b   Suzuki, Takayo ^c   Utsunomiya, Atae ^d   Matsuda, Shin ^e   Chou, Takaaki ^f   Sai, Toshiaki ^g   Sano, Masayuki ^h   Konda, Susumu ⁱ   Ohno, Tatsuji ^j   Mikuni, Chikara ^k   Deura, Kijoh ^l   Yamada, Takashi ^m   Mizorogi, Fumi ⁿ   Nagoshi, Haruhisa ^o   Tomonaga, Masao ^p   Hotta, Tomomitsu ^q   Kawano, Kohichi ^r   Tsushita, Keitaro ^s   Hirano, Masami ^t   Shimoyama, Masanori ^a   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c Shiga Medical Center for Adult Diseases   (Japan)

^d IMAMURA BUN IN HOSPITAL   (Japan)

^e OHTA NISHINOUCHI HOSPITAL   (Japan)

^f NIIGATA CANCER CENTER HOSPITAL   (Japan)

^g Iwaki Kyoritsu General Hospital   (Japan)

^h SAGA UNIVERSITY   (Japan)

ⁱ KANAZAWA MEDICAL UNIVERSITY   (Japan)

^j OTSU RED CROSS HOSPITAL   (Japan)

^k HOKKAIDO CANCER CENTER   (Japan)

^l Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^m Jikei University Katsushika Medical Center   (Japan)

ⁿ JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

^p NAGASAKI UNIVERSITY   (Japan)

^q TOKAI UNIVERSITY   (Japan)

^r KYORIN UNIVERSITY   (Japan)

^s NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^t FUJITA HEALTH UNIVERSITY   (Japan)

more..

Author keywords

Combination chemotherapy; MP; Multiple myeloma; Randomized study; Ranimustine

Indexed keywords

CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISOLONE; RANIMUSTINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSESTHESIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; HYPOXEMIA; INFECTION; JAPAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 10744224509     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.03115     Document Type: Article

References (39)

1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
2. Takenaka T, Shirakawa S, Mikuni C, et al. Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisolone) and MP (melphalan, prednisolone) in multiple myeloma: a multicenter phase II study (JCOG8906). Jpn J Clin Oncol. 1999;29: 485-489.
3. Tanaka I, Kobayashi T, Shirakawa S, et al. Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureoid]-6-deoxy-α-D-glucopyranoside (MCNU) [in Japanese with English summary]. Jpn J Cancer Chemother. 1985;12:493-498.
4. Imamura Y, Takagi T, Yawata Y, et al. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Int J Hematol. 1994;59:113-123.
5. Wada M, Mizoguchi H, Kuriya S, et al. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon α (ROAD-IN) and a randomized comparison of interferon α maintenance in multiple myeloma: a co-operative study in Japan. Br J Haematol. 2000;109:805-814.
6. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
8. Shimoyama M, Fukuda H, Saijo N, Yamaguchi N. Japan Clinical Oncology Group (J COG). Jpn J Clin Oncol. 1998;28:158-162.
9. Salmon SE, Haut A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improve survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1983; 1:453-461.
10. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23: 250-257.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Cox DR. Regression models and life-tables. J R Stat Soc Series B. 1972;34:187-220.
13. Kim K, DeMets DL. Confidence intervals following group sequential tests in clinical trials. Biometrics. 1987;43:857-864.
14. Reboussin DM, DeMets DL, Kim KM, Lan KKG. Programs for computing group sequential boundaries using the Lan-DeMets methods version 2 (1998). Available at: http://www.medsch.wisc.edu/landemets/.
15. SAS/ATAT Software: Changes and Enhancements for Release 6.12. Cary, NC: SAS Institute; 1997.
16. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:334-342.
17. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
18. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999; 93:51-54.
19. Sirohi B, Powles R, Treleaven J, et al. High-dose chemotherapy and autologous transplantation in myeloma patients aged 65 years and over: a case-control comparison with younger patients. Blood. 1999;94:578a.
20. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview on 24 randomized trials and 4012 patients. Br J Haematol. 2001;113: 1020-1034.
21. Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1998;16:890-896.
22. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of α-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol. 2000;65: 204-209.
23. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: 1561-1571.
24. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000; 109:89-96.
25. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
26. Hussein MA, Elson P, Tose EA, Karam M, Srkaloci G. Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma [abstract]. Blood 2002(suppl 1);100:403a.
27. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002:100: 3063-3067.
28. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
29. Richardson P, Barlogie B, Berenson J, et al. A phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™, formerly PS-341) in multiple myeloma patients with relapsed/refractory disease [abstract]. Blood. 2002(suppl 1);100:104a.
30. Zangari M, Barlogie B, Prather J, et al. Marked activity also in del 13 multiple myeloma of PS 341 and subsequent thalidomide in a setting of resistance to post-autotransplant salvage therapies [abstract]. Blood. 2002(suppl 1);100:105a.
31. Pinto OC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govidarajan B. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878-884.
32. Ohtsu T, Sai T, Oka M, Sugai Y, Tobinai K. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematological malignancies. Jpn J Clin Oncol. 1991;21:360-365.
33. Yoshiba M, Sekiyama K, Iwabuchi S, et al. Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy. Dig Dis Sci. 1993;38:1751-1755.
34. Fan FS, Tzeng CH, Hsiao KI, Hu ST, Liu WT, Chen PM. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant. 1991;8:417-420.
35. Fong T-L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 1994;107:196-199.
36. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347:92-93.
37. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743-748.
38. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318:76-81.
39. Boffetta P, Kaldor JM. Secondary malignancies following cancer chemotherapy. Acta Oncol. 1994;33:591-598.